News

The Pharma Letter8m
Galderma aids Nemluvio launch by expanding evidence base
Swiss skincare specialist Galderma has announced two-year data from a new interim analysis of a long-term extension study ...
The Pharma Letter36m
Rare disease patients sound alarm on Denmark’s health reform
As Denmark presses ahead with a major health reform, a coalition of rare disease advocates and clinicians is urging the ...
The Pharma Letter58m
Sanofi moves early on Beyfortus shipments to get ahead of demand
French pharma major Sanofi (Euronext: SAN) has started early global shipments of its monoclonal antibody Beyfortus ...
The Pharma Letter1h
Knight Therapeutics gains rights to Sumitomo Pharma products in Canada
Knight will have the exclusive rights to distribute, promote, market and sell the products in Canada, and said it will begin ...
The Pharma Letter1h
India seizes $41 billion Russian pharma opportunity
The Russian pharmaceutical market, valued at around $41 billion, continues to be a magnet for Indian pharmaceutical companies ...
The Pharma Letter1h
Dupixent success in patients with darker skin tones with atopic dermatitis
US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) and French pharma major Sanofi (Euronext: SAN) on Saturday presented ...
The Pharma Letter1h
EU Council agrees on the revision of the general pharma legislation
The European Council of Minister last week said it is ready to begin negotiations with the European Parliament, having agreed ...
The Pharma Letter1h
PureTech eyes a pivotal role in lung fibrosis treatment with LYT-100
US biotech PureTech Health (Nasdaq: PRTC) is positioning its lead candidate LYT-100 as a potential disruptor in the treatment of idiopathic pulmonary fibrosis (IPF), a rare lung condition long ...